Related Experiment Video
Updated: Jan 12, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Comparative Effects of P2Y12 Inhibitors on Thrombus Biology and Inflammatory Responses in Atherothrombotic
Najeeb Ullah1,2, Muhammad Ali1, Irum Dad Khan3
1Internal Medicine, Royal Derby Hospital, Derby, GBR.
Abstract:
This systematic review investigates the biological impact of various P2Y12 receptor inhibitors on thrombus composition and inflammatory activity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI). A comprehensive literature search across four major databases identified four randomized controlled trials that met the inclusion criteria for evidence synthesis. These trials examined ticagrelor, prasugrel, cangrelor, and genotype-guided strategies in comparison to clopidogrel, assessing outcomes such as inflammatory cell infiltration, platelet reactivity, and myocardial reperfusion parameters. Overall, ticagrelor and prasugrel were associated with more favorable modulation of thromboinflammatory and vascular healing markers compared with clopidogrel; these effects were most evident in studies evaluating neutrophil infiltration, myeloperoxidase activity, and early post-PCI ischemic events. However, variations in study design, endpoints, and follow-up duration limited direct comparisons and precluded definitive conclusions. In addition, one mechanistic study protocol describing the assessment of extracellular vesicle-based biomarkers was identified but excluded from the evidence synthesis due to the absence of outcome data. Collectively, the available evidence provides preliminary mechanistic support for the hypothesis that certain P2Y12 inhibitors may exert anti-inflammatory and thrombus-modifying effects beyond their platelet-inhibiting effects. Larger, standardized, and mechanistically focused trials are warranted to validate these findings and guide precision-based antiplatelet therapy in cardiovascular disease.
Insights
Certain P2Y12 inhibitors like ticagrelor and prasugrel show anti-inflammatory effects beyond platelet inhibition in acute coronary syndrome patients. More research is needed to confirm these benefits for personalized antiplatelet therapy.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Acute coronary syndromes (ACS) require antiplatelet therapy, with P2Y12 inhibitors being crucial.
- Percutaneous coronary intervention (PCI) is a common treatment for ACS.
- Understanding the broader biological impact of P2Y12 inhibitors beyond platelet inhibition is essential for optimizing patient outcomes.
Purpose of the Study:
- To systematically review the biological effects of P2Y12 receptor inhibitors on thrombus composition and inflammation in ACS patients post-PCI.
- To compare the anti-inflammatory and vascular healing effects of ticagrelor, prasugrel, and cangrelor against clopidogrel.
Main Methods:
- Systematic literature search of four databases for randomized controlled trials (RCTs).
- Inclusion of four RCTs comparing ticagrelor, prasugrel, cangrelor, or genotype-guided therapy with clopidogrel.
- Assessment of inflammatory markers, platelet reactivity, and reperfusion parameters.
Main Results:
- Ticagrelor and prasugrel demonstrated more favorable modulation of thromboinflammatory markers and vascular healing compared to clopidogrel.
- Observed benefits were linked to reduced neutrophil infiltration, myeloperoxidase activity, and fewer early post-PCI ischemic events.
- Study variations limited definitive comparisons and conclusions.
Conclusions:
- Preliminary evidence suggests P2Y12 inhibitors may possess anti-inflammatory and thrombus-modifying properties independent of their antiplatelet action.
- Larger, standardized trials focusing on mechanisms are required to validate these findings.
- Results may guide precision-based antiplatelet therapy in cardiovascular disease.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...